List view / Grid view
28 September 2016 | By Niamh Louise Marriott, Digital Content Producer
Approximately 10% of the general population suffer from onychomycosis and a majority of those afflicted go untreated. The prescription market is growing...
22 March 2016 | By Victoria White
BUPI is a patent pending lozenge formulation of bupivacaine for pain management in oral mucositis in cancer patients...
11 January 2016 | By Victoria White
Oral mucositis is a common and often debilitating complication of cancer treatment which affects 80% of patients with head and neck cancer receiving radiotherapy...
26 March 2015 | By Victoria White
Moberg Pharma today announced that the European Patent Office has issued a Patent relating to its topical treatment MOB-015 for onychomycosis (nail fungus)...
25 March 2015 | By Victoria White
Moberg Pharma have announced that the United States Patent and Trademark Office has issued a patent for Moberg Pharma’s market-leading product Kerasal Nail...
27 February 2015 | By Moberg Pharma
Successful fourth quarter and the first profitable full year...
18 February 2015 | By Moberg Pharma
On February 27, at 08:00 CET, Moberg Pharma AB (OMX: MOB) will publish its report for the fourth quarter and full year 2014...
13 February 2015 | By Moberg Pharma
Moberg Pharma AB announced that it shipped opening orders of its new line extension, Kerasal® Complete Care in Walgreens, the #1 drug chain in the U.S., with additional retailers expected to follow...
9 February 2015 | By Moberg Pharma
Moberg Pharma AB announced that Berlin-Chemie AG, a member of the Menarini Group – a top 40 global pharmaceutical company – has been granted the exclusive rights to market and sell Emtrix® in Russia and Ukraine...
27 January 2015 | By Moberg Pharma
Moberg Pharma AB announced that its partner, Menarini Asia-Pacific, has received approval for Moberg’s fungal nail product in China...
20 November 2014 | By Moberg Pharma
Moberg Pharma AB have appointed Jeff Vernimb as General Manager for its U.S. operations and a member of Moberg’s Management Team – effective from December 15, 2014...
17 November 2014 | By Moberg Pharma
Moberg Pharma AB announces that George E. Aitken-Davies has resigned from the Board of Directors of Moberg Pharma in conjunction with the final earn-out payment related to the acquisition of Alterna LLC in 2012...
17 November 2014 | By Moberg Pharma
"We made excellent progress in the third quarter, growing at 35% with improved profitability and reporting strong phase II data for MOB-015 in nail fungus..."
14 November 2014 | By Moberg Pharma
Moberg Pharma’s partner in Southeast Asia and China, Menarini APAC, has initiated the launch in Malaysia of Moberg Pharma’s prescription-free treatment for nail fungus...
11 November 2014 | By Moberg Pharma
In accordance with the resolution of the Annual General Meeting on May 13, 2014, the Chairman of the Board has contacted the company’s three largest shareholders or group of shareholders in terms of votes to form a Nomination Committee...
